Skip to content
  • info@BioLifeSolutions.com
  • 1.866.424.6543
  • Toggle search form
  • Toggle shopping cart 0

    Cart

  • Products
    • CryoStor®
      • CryoStor CS10
      • CryoStor CS5
      • CryoStor CS2
    • HypoThermosol®
      • HypoThermosol®
      • HypoThermosol for Hair
    • BloodStor®
      • BloodStor 100
      • BloodStor 55-5
      • BloodStor 27
    • Cell Thawing Media®
      • 10% Dextran 40 (IN 0.9% NaCl)
      • 10% Dextran 40 (IN 5% Dextrose)
    • All Products
  • Resources
    • Certificate of Analysis
    • Blog
    • Events
    • BioPreservation Today
    • White Papers
    • Press Releases
  • Evidence
    • Resource Links
  • Company
    • About
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
    • Quality & Regulatory Systems
    • Distributors
    • Current Job Openings
  • Investors
    • Investors Home
    • Governance
    • Press Releases
    • Financials
    • Stock Information
    • Management Team
    • Investor Contact
  • Contact
    • General Inquiries
    • Master File Request
    • SDS Request Form
    • Sample Request
  • Ask the Scientists
  • ORDER
Close navigation
  • Primary Menu
BioLife Solutions

BioLife Solutions

Biopreservation Tools For Cells, Tissues, and Organs

Close search

Search

Search for:
Home/Blog/Tag: “DLBCL”

Tag: DLBCL

Improving T-cell expansion and function for adoptive T-cell therapy using ex vivo treatment with PI3Kδ inhibitors and VIP antagonists

Petersen, Hassan, Morris, Jeffery, Lee, Jagirdar, Staton, Raikar, Spencer, Sulchek, Flowers, Waller. Improving T-cell expansion and function for adoptive T-cell therapy using ex vivo treatment with PI3Kδ inhibitors and VIP antagonists. Blood Advances 2018 2:210-223. DOI 10.1182/bloodadvances.2017011254

ALLogeneic Heart STem Cells to Achieve Myocardial Regeneration (ALLSTAR) Trial: Rationale and Design

Chakravarty T, Makkar RR, Ascheim DD, Traverse JH, Schatz R, DeMaria A, Francis GS, Povsic TJ, Smith RR, Lima JA, Pogoda JM, Marbán L, Henry TD ALLogeneic Heart STem Cells to Achieve Myocardial Regeneration (ALLSTAR) Trial: Rationale and Design Cell Transplant. 2017 Feb 16;26(2):205-214 DOI: 10.3727/096368916X692933

Search for:

Blog Archives

Signup Area

Sign Up for Email Updates

Biolife Logo

  • Products
  • Company
  • Evidence
  • Investors
  • Blog
  • Ask the Scientists
  • Press Releases
  • Contact
© 2018 BioLifeSolutions Inc.  All Rights Reserved    |    Terms & Conditions    |    Privacy
  • twitter
  • linkedin
  • facebook